|
1
|
Gerstner ER and Batchelor TT: primary
central nervous system lymphoma. Arch Neurol. 67:291–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Senocak E, Oguz KK, Ozgen B, et al:
Parenchymal lymphoma of the brain on initial MR imaging: A
comparative study between primary and secondary brain lymphoma. Eur
J Radiol. 79:288–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kluin PM, Deckert M and Ferry JA: Primary
diffuse large B-cell lymphoma of the CNS. WHO Classification of
Tumours of Haematopietic and Lymphoid Tissues. Swerdlow SH, Campo
E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman
JW: 2:(4th). IARC Press. (Lyon). 240–241. 2008.
|
|
4
|
del Rio Sierra M, Rousseau A, Soussain C,
Ricard D and Hoang-Xuan K: Primary CNS lymphoma in immunocompetent
patients. Oncologist. 14:526–539. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li Y, Liu F, Liu Y and Zhang J: The
diagnosis and treatment of primary central nervous system lymphoma.
Zhonghua Xue Ye Xue Za Zhi. 35:771–773. 2014.(In Chinese).
PubMed/NCBI
|
|
6
|
Aki H, Uzunaslan D, Saygin C, Batur S,
Tuzuner N, Kafadar A, Ongoren S and Oz B: Primary central nervous
system lymphoma in immunocompetent individuals: A single center
experience. Int J Clin Exp Pathol. 6:1068–1075. 2013.PubMed/NCBI
|
|
7
|
Ferreri AJ and Marturano E: primary CNS
lymphoma. Best Pract Res Clin Haematol. 25:119–130. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soussain C and Hoang-Xuan K: primary
central nervous system lymphoma: An update. Curr Opin Oncol.
21:550–558. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mrugala MM, Rubenstein JL, Ponzoni M and
Batchelor TT: Insights into the biology of primary central nervous
system lymphoma. Curr Oncol Rep. 11:73–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haque S, Law M, Abrey LE and Young RJ:
Imaging of lymphoma of the central nervous system, spine, and
orbit. Radiol Clin North Am. 46:339–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Server A, Josefsen R, Kulle B, Maehlen J,
Schellhorn T, Gadmar Ø, Kumar T, Haakonsen M, Langberg CW and
Nakstad PH: Proton magnetic resonance spectroscopy in the
distinction of high-grade cerebral gliomas from single metastatic
brain tumors. Acta Radiol. 51:316–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barajas RF Jr, Rubenstein JL, Chang JS,
Hwang J and Cha S: Diffusion-weighted MR imaging derived apparent
diffusion coefficient is predictive of clinical outcome in primary
central nervous system lymphoma. AJNR Am J Neuroradiol. 31:60–66.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mohile NA, Deangelis LM and Abrey LE: The
utility of body FDG PET in staging primary central nervous system
lymphoma. Neuro Oncol. 10:223–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karantanis D, O'eill BP, Subramaniam RM,
Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ and Wiseman GA:
18F-FDG PET/CT in primary central nervous system lymphoma in
HIV-negative patients. Nucl Med Commun. 28:834–841. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawai N, Okubo S, Miyake K, Maeda Y,
Yamamoto Y, Nishiyama Y and Tamiya T: Use of PET in the diagnosis
of primary CNS lymphoma in patients with atypical MR findings. Ann
Nucl Med. 24:335–343. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raoux D, Duband S, Forest F, Trombert B,
Chambonnière ML, Dumollard JM, Khaddage A, Gentil-Perret A and
Péoc'h M: primary central nervous system lymphoma:
Immunohistochemical profile and prognostic significance.
Neuropathology. 30:232–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kinoshita M, Hashimoto N, Izumoto S, Okita
Y, Kagawa N, Maruno M, Ohnishi T, Arita N and Yoshimine T:
Immunohistological profiling by B-cell differentiation status of
primary central nervous system lymphoma treated by high-dose
methotrexate chemotherapy. J Neurooncol. 99:95–101. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kleihues P and Cavenee WK: Pathology and
Genetics of Tumours of the Nervous System. IARC Press. Lyon:
198–203. 2000.
|
|
19
|
Angelov L, Doolittle ND, Kraemer DF,
Siegal T, Barnett GH, Peereboom DM, Stevens G, McGregor J, Jahnke
K, Lacy CA, et al: Blood-brain barrier disruption and
intra-arterial methotrexate-based therapy for newly diagnosed
primary CNS lymphoma: A multi-institutional experience. J Clin
Oncol. 27:3503–3509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang D, Hu LB, Henning TD, Ravarani EM,
Zou LG, Feng XY, Wang WX and Wen L: MRI findings of primary CNS
lymphoma in 26 immunocompetent patients. Korean J Radiol.
11:269–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Basso U and Brandes AA: Diagnostic
advances and new trends for the treatment of primary central
nervous system lymphoma. Eur J Cancer. 38:1298–1312. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang Y, He J, Dang Y, Xia X, Dai Y and Xu
R: One case report and literature review of primary central nervous
system non Hodgkin's lymphoma. Lin Chuang Shen Jing Wai Ke Za Zhi.
5:373–375. 2014.(In Chinese).
|
|
23
|
Abrey LE, Yahalom J and DeAngelis LM:
Treatment for primary CNS lymphoma: The next step. J Clin Oncol.
18:3144–3150. 2000.PubMed/NCBI
|
|
24
|
Glantz MJ, Cole BF, Recht L, Akerley W,
Mills P, Saris S, Hochberg F, Calabresi P and Egorin MJ: High-dose
intravenous methotrexate for patients with nonleukemic
leptomeningeal cancer: Is intrathecal chemotherapy necessary? J
Clin Oncol. 16:1561–1567. 1998.PubMed/NCBI
|
|
25
|
Guha-Thakurta N, Damek D, Pollack C and
Hochberg FH: Intravenous methotrexate as initial treatment for
primary central nervous system lymphoma: Response to therapy and
quality of life of patients. J Neurooncol. 43:259–268. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murakami M, Fujimaki T, Asano S, Nakaguchi
H, Yamada SM, Hoya K, Yamazaki K, Ishida Y and Matsuno A:
Combination therapy with rituximab and temozolomide for recurrent
and refractory primary central nervous system lymphoma. Yonsei Med
J. 52:1031–1034. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Makino K, Nakamura H, Hide T and Kuratsu
J: Salvage treatment with temozolomide in refractory or relapsed
primary central nervous system lymphoma and assessment of the MGMT
status. J Neurooncol. 106:155–160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamanaka R, Morii K, Shinbo Y, Homma J,
Sano M, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, et
al: Results of treatment of 112 cases of primary CNS lymphoma. Jpn
J Clin Oncol. 38:373–380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weaver JD, Vinters HV, Koretz B, Xiong Z,
Mischel P and Kado D: Lymphomatosis cerebri presenting as rapidly
progressive dementia. Neurologist. 13:150–153. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suh C, Kim JE and Yoon DH: Relapse pattern
and prognostic factors for patients with primary CNS lymphoma.
Korean J Hematol. 47:155–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
